Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824482 | 1.00 | KDM4E (0.46) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| Hydrochloric Acid SCHEMBL28102802 | 0.98 | KDM4E (0.44) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| Hydrochloric Acid SCHEMBL28174209 | 0.98 | KDM4E (0.44) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL3277330 | 0.83 | KDM4E (0.45) | KDM4ECYP1A2HTR3AHRH4GPR3 | |
| SCHEMBL27825404 | 0.81 | CYP1A2 (0.38) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL28624806 | 0.80 | CYP1A2 (0.40) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL3634933 | 0.80 | TLR8 (0.49) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL30952029 | 0.80 | TLR8 (0.49) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL716117 | 0.80 | TSHR (0.50) | KDM4ETLR8CYP1A2HTR3AHRH4 | |
| SCHEMBL5004880 | 0.79 | TLR8 (0.47) | KDM4ETLR8CYP1A2HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-11-07 | — | — | US | claimed |
| WO-2012070040-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2012-05-31 | — | — | WO | claimed |
| EP-2303255-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF CANCERS, IN PARTICULAR ACUTE MYELOID LEUKEMIA AND ACUTE PROMYELOCYTIC LEUKEMIA | Université Paris Diderot - Paris 7 (FR) | 2011-04-06 | — | — | EP | claimed |
| WO-2009147169-A1 | PHARMACEUTICL COMPOSITIONS USEFUL FOR THE TREATMENT OF CANCERS, IN PARTICULAR ACUTE MYELOID LEUKEMIA AND ACUTE PROMYELOCYTIC LEUKEMIA | UNIVERSITE PARIS DIDEROT-PARIS 7 (FR) | 2009-12-10 | — | — | WO | claimed |
| EP-2086641-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008049842-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | claimed |
| EP-1845992-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | Boehringer Ingelheim International GmbH (DE) | 2007-10-24 | — | — | EP | claimed |
| JP-2007517819-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1706119-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | claimed |
| WO-2006082129-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | WO | claimed |
| WO-2005065687-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | claimed |
| WO-2004026319-A2 | PHARMACEUTICAL COMPOSITIONS INCREASING CAMP USEFUL FOR THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-04-01 | — | — | WO | claimed |
| US-4212937-A | NITROGEN-CONTAINING HETEROCYCLIC BASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-07-15 | — | — | US | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1988008841-A1 | AMINO-4 QUINAZOLINEDIONE-5,8 DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1988-11-17 | — | — | WO | disclosed |
| US-4212937-A | NITROGEN-CONTAINING HETEROCYCLIC BASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | KDM4E 2411/4885TLR8 3054/4885CYP1A2 2295/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | KDM4E 3667/4885TLR8 927/4885CYP1A2 1183/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | KDM4E 4583/4885TLR8 1054/4885CYP1A2 877/4885 |
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | PDE3B, PDE3A, PDE2A | KDM4E 2463/4885TLR8 2619/4885CYP1A2 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.